Crohn's disease pathophysiology
Jump to navigation
Jump to search
|
Crohn's disease |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Crohn's disease pathophysiology On the Web |
|
American Roentgen Ray Society Images of Crohn's disease pathophysiology |
|
Risk calculators and risk factors for Crohn's disease pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Aditya Ganti M.B.B.S. [3]
Overview
Crohn's disease (CD) arises when environmental triggers and gut microbial dysbiosis provoke a poorly regulated mucosal immune response across an impaired epithelial barrier in a genetically susceptible host.[1][2] No single gene, microbe, or environmental factor is sufficient on its own. The result is a self-perpetuating cycle of barrier breakdown, microbial translocation, and Th1/Th17-skewed transmural inflammation, which current therapies interrupt at specific points.[3][2] More than 200 susceptibility loci have been identified. They converge on four processes: innate microbial sensing (NOD2), autophagy (ATG16L1), epithelial barrier integrity, and IL-23/Th17 signaling.[4][5] The hallmark pathologic features are:
- Transmural inflammation
- Skip lesions
- Non-caseating granulomas
- A propensity for stricture and fistula formation
Pathophysiology
Unifying Model
CD reflects the interplay of four interdependent elements rather than a linear sequence:[1][3][2]
- Genetic susceptibility lowers the threshold for immune activation.
- Environmental triggers act largely through the microbiome and the epithelial barrier. These include smoking, diet, antibiotic exposure, and enteric infection.
- Microbial dysbiosis expands pathobionts and depletes protective commensals.
- Dysregulated innate and adaptive immunity produces transmural, granulomatous inflammation.
The genetics point to a "network dyshomeostasis" across interconnected pathways rather than a single defective pathway. These pathways cover microbial sensing, barrier integrity, autophagy, cytokine signaling, and cell-stress responses.[5]
Genetic Susceptibility
- Genome-wide association studies have identified more than 200 inflammatory bowel disease (IBD) risk loci, which confirms a polygenic architecture.[1][4]
- Most loci confer only modest risk (odds ratios ~1.1–1.2) and lie in regulatory regions. Known variants explain only roughly 19–26% of CD heritability, which underscores the contribution of environment and gene–environment interaction.[6]
- Monozygotic twin concordance is approximately 50% in CD, compared with approximately 15% in ulcerative colitis (UC).[4]
- Risk alleles differ by ancestry:[4]
- Coding variants in NOD2, ATG16L1, and IL23R predominate in populations of European ancestry.
- These variants are essentially monomorphic in East Asian cohorts, where TNFSF15 is the leading CD locus.
| Gene / pathway | Mechanism | Clinical correlation |
|---|---|---|
| NOD2 (CARD15) | Intracellular sensor of bacterial muramyl dipeptide. CD-associated variants, such as the c.3019–3020insC frameshift, cause loss of function. This impairs bacterial recognition, Paneth cell antimicrobial peptide secretion, and autophagy.[4][7][8] | First and strongest CD-specific locus. Associated with ileal and fibrostenosing disease.[9][7] |
| ATG16L1, IRGM, LRRK2' (autophagy) | The ATG16L1 p.Thr300Ala variant increases caspase-3 cleavage of ATG16L1. This impairs clearance of intracellular bacteria and Paneth-cell function. NOD2 recruits ATG16L1 to sites of bacterial entry, so both genes converge on defective autophagy.[4][10][11] | ATG16L1 risk allele predisposes to ileal CD, independent of NOD2.[12] |
| IL23R and Th17 axis (IL12B, JAK2, STAT3, CCR6, TNFSF15) | Regulate IL-23-driven Th17 responses. Some IL23R variants are protective.[13][14] | Provides the genetic rationale for IL-12/23 and IL-23 blockade and for JAK inhibition. |
| ER-stress / unfolded protein response (XBP1, ORMDL3) | Epithelial ER stress is intertwined with autophagy at the epithelial–microbial interface.[10] | Links Paneth-cell dysfunction to ileal inflammation. |
- CD remains a clinical diagnosis. Routine genotyping is not part of standard care.
Intestinal Epithelial Barrier
- An impaired epithelial barrier is now viewed as a central pathogenic factor rather than a bystander.[1]
- Several defects allow luminal bacteria and metabolites to reach the lamina propria and activate immune cells:[15][16]
- Reduced mucus
- Dysregulated tight junctions
- Fewer or dysfunctional Paneth cells with impaired antimicrobial peptide secretion
- Reduced intestinal stem cell function
- Barrier dysfunction and subclinical gut inflammation have been detected before clinically overt CD in at-risk individuals. This supports an upstream, potentially causal role.[17]
- Environmental exposures, including smoking, are best understood as acting through the barrier and the microbiome. Psychological stress may modulate disease course but is not a core etiologic pillar.[17][18]
Microbiome and Dysbiosis
- The microbiota is essential to CD pathogenesis, but no single causative pathogen has been identified.[3][6]
- CD is characterized by reduced microbial diversity, with two main shifts:[1][15]
- Loss of Firmicutes, notably the butyrate producers Faecalibacterium prausnitzii and Roseburia spp.
- Expansion of Proteobacteria, including adherent-invasive Escherichia coli (AIEC).
- In the pathobiont concept, otherwise commensal organisms become pathogenic under disease-promoting host conditions. Dysbiosis is both a cause and a consequence of inflammation.[3][2]
- Inflammation itself drives "late dysbiosis." It increases luminal oxygen, nitrate, and iron, which favors facultative anaerobes.[7]
- Loss of protective microbial metabolites further weakens barrier and immune homeostasis. These metabolites include short-chain fatty acids, secondary bile acids, and tryptophan/indole derivatives.[19]
Innate Immunity
- CD shows deficient innate responses, including reduced macrophage bactericidal activity and impaired neutrophil recruitment. These deficits permit microbial persistence and translocation.[20]
- NLRP3 inflammasome activation processes IL-1β and IL-18.[20]
- Lamina propria macrophages that engulf penetrating bacteria secrete TNF, IL-6, IL-12, and IL-23.[16]
- Dendritic cells present luminal antigens and polarize naive T cells toward inflammatory effector phenotypes.[4]
Adaptive Immunity
- CD is driven by excessive Th1 and Th17 responses to IL-12, IL-18, and IL-23 from antigen-presenting cells, together with impaired regulatory T cell function.[13][4]
- Th1/Th17 cells secrete IFN-γ, IL-17, and TNF, which perpetuate transmural inflammation.[4][20]
- The characteristic granuloma reflects this cell-mediated, rather than antibody-mediated, response.[4]
- The older strict "Th1 = CD, Th2 = UC" paradigm has been revised. Th17 cells and the IL-12/IL-23 axis are now recognized as central drivers. The two cytokines share the p40 subunit.[13]
- Gut-selective lymphocyte trafficking depends on α4β7 integrin–MAdCAM-1 interactions, a validated therapeutic target.[4][18]
| Pathway node | Role in CD | Drug class (examples) |
|---|---|---|
| TNF | Central effector cytokine. Drives macrophage activation, adhesion molecule expression, and epithelial injury. | Anti-TNF antibodies (infliximab, adalimumab, certolizumab pegol) |
| IL-12/IL-23 (shared p40) | Drives both Th1 (IL-12) and Th17 (IL-23) differentiation. | Anti-p40 (ustekinumab) |
| IL-23 (p19) | Maintains pathogenic Th17 cells. | Anti-p19 antibodies (risankizumab, mirikizumab, guselkumab) |
| JAK–STAT signaling | Transduces multiple proinflammatory cytokine signals. | JAK inhibitors (upadacitinib) |
| α4β7–MAdCAM-1 | Gut-specific homing of effector lymphocytes. | Anti-α4β7 (vedolizumab) |
Fibrostenosis and Penetrating Disease
- Chronic transmural inflammation activates fibroblasts and other mesenchymal cells, including through oncostatin M signaling. This produces the strictures and penetrating/fistulizing complications that distinguish CD from UC.[14][5]
- Fibrosis may progress despite control of inflammation. No therapy is approved to reverse established fibrostenosis.[14]
Gross Pathology
- Transmural, patchy inflammation with skip lesions. The terminal ileum and proximal colon are involved most often.[2]
- Creeping fat (mesenteric fat wrapping) and a thickened, rubbery bowel wall.[4]
- Strictures, which appear as the string sign on contrast imaging.
- Aphthous ulcers that progress to linear ulcers, cobblestoning, fissures, and fistulas.[4]
Microscopic Pathology
- Transmural inflammation with lymphoid aggregates throughout the bowel wall.[4]
- Focal crypt injury:
- Neutrophilic infiltration of crypts, causing cryptitis or crypt abscess
- Crypt architectural distortion and branching
- Non-caseating granulomas are highly specific for CD but are present in only a subset of cases. Their absence does not exclude the diagnosis.[4]
- Paneth cell metaplasia and villous blunting.[22]
Source: Samir at English Wikipedia, GFDL/CC-BY-SA-3.0, via Wikimedia Commons
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Dolinger M, Torres J, Vermeire S (2024). "Crohn's disease". Lancet. 403 (10432): 1177–1191. doi:10.1016/S0140-6736(23)02586-2.
- ↑ 2.0 2.1 2.2 2.3 2.4 Caruso R, Lo BC, Chen GY, Núñez G (2025). "Host–pathobiont interactions in Crohn's disease". Nat Rev Gastroenterol Hepatol. 22 (6): 395–414. doi:10.1038/s41575-024-00997-y.
- ↑ 3.0 3.1 3.2 3.3 Kennedy MS, Chang EB (2025). "Emerging concepts and shifting paradigms for understanding the microbial basis of inflammatory bowel diseases". J Clin Invest. 135 (17): e193969. doi:10.1172/JCI193969.
- ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 Roda G, Chien Ng S, Kotze PG; et al. (2020). "Crohn's disease". Nat Rev Dis Primers. 6 (1): 22. doi:10.1038/s41572-020-0156-2.
- ↑ 5.0 5.1 5.2 Graham DB, Xavier RJ (2020). "Pathway paradigms revealed from the genetics of inflammatory bowel disease". Nature. 578 (7796): 527–539. doi:10.1038/s41586-020-2025-2.
- ↑ 6.0 6.1 Gilliland A, Chan JJ, De Wolfe TJ, Yang H, Vallance BA (2024). "Pathobionts in inflammatory bowel disease: origins, underlying mechanisms, and implications for clinical care". Gastroenterology. 166 (1): 44–58. doi:10.1053/j.gastro.2023.09.019.
- ↑ 7.0 7.1 7.2 Caruso R, Lo BC, Núñez G (2020). "Host–microbiota interactions in inflammatory bowel disease". Nat Rev Immunol. 20 (7): 411–426. doi:10.1038/s41577-019-0268-7.
- ↑ Ogura Y, Bonen DK, Inohara N; et al. (2001). "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease". Nature. 411 (6837): 603–6.
- ↑ Cuthbert AP, Fisher SA, Mirza MM; et al. (2002). "The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease". Gastroenterology. 122 (4): 867–74. PMID 11910337.
- ↑ 10.0 10.1 Fritz T, Niederreiter L, Adolph T, Blumberg RS, Kaser A (2011). "Crohn's disease: NOD2, autophagy and ER stress converge". Gut. 60 (11): 1580–8. doi:10.1136/gut.2009.206466.
- ↑ Cohen LJ, Cho JH, Gevers D, Chu H (2019). "Genetic factors and the intestinal microbiome guide development of microbe-based therapies for inflammatory bowel diseases". Gastroenterology. 156 (8): 2174–2189. doi:10.1053/j.gastro.2019.03.017.
- ↑ Prescott NJ, Fisher SA, Franke A; et al. (2007). "A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5". Gastroenterology. 132 (5): 1665–71. PMID 17484864.
- ↑ 13.0 13.1 13.2 Brand S (2009). "Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease". Gut. 58 (8): 1152–67. doi:10.1136/gut.2008.163667.
- ↑ 14.0 14.1 14.2 Jia L, Wang H (2026). "Crohn's disease enteritis: pathophysiological mechanisms and therapeutic approaches". Scand J Immunol. 103 (6): e70129. doi:10.1111/sji.70129.
- ↑ 15.0 15.1 Kou R, Guo Y, Qin Z; et al. (2025). "Systemic dysregulation of the gut microenvironment plays a pivotal role in the onset and progression of inflammatory bowel disease". Front Immunol. 16: 1661386. doi:10.3389/fimmu.2025.1661386.
- ↑ 16.0 16.1 16.2 Chang JT (2020). "Pathophysiology of inflammatory bowel diseases". N Engl J Med. 383 (27): 2652–2664. doi:10.1056/NEJMra2002697.
- ↑ 17.0 17.1 Xue M, Leibovitzh H, Jingcheng S; et al. (2024). "Environmental factors associated with risk of Crohn's disease development in the Crohn's and Colitis Canada – Genetic, Environmental, Microbial Project". Clin Gastroenterol Hepatol. 22 (9): 1889–1897.e12. doi:10.1016/j.cgh.2024.03.049.
- ↑ 18.0 18.1 Neurath MF (2019). "Targeting immune cell circuits and trafficking in inflammatory bowel disease". Nat Immunol. 20 (8): 970–979. doi:10.1038/s41590-019-0415-0.
- ↑ Liang Y, Zhou Y, Luo P, Lin J (2026). "Gut microbiota metabolites in inflammatory bowel disease: advances in mechanistic insights". Front Immunol. 17: 1827426. doi:10.3389/fimmu.2026.1827426.
- ↑ 20.0 20.1 20.2 Ruiz Castro PA, Yepiskoposyan H, Gubian S; et al. (2021). "Systems biology approach highlights mechanistic differences between Crohn's disease and ulcerative colitis". Sci Rep. 11 (1): 11519. doi:10.1038/s41598-021-91124-3.
- ↑ Neurath MF (2017). "Current and emerging therapeutic targets for IBD". Nat Rev Gastroenterol Hepatol. 14 (5): 269–278. doi:10.1038/nrgastro.2016.208.
- ↑ Crawford JM. The gastrointestinal tract. In: Cotran RS, Kumar V, Robbins SL, eds. Robbins Pathologic Basis of Disease. 5th ed. Philadelphia: WB Saunders; 1994.